$MBINM

Merchants Bancorp shares drop 9.3% after Q1 earnings reveal sharp deposit decline and rising funding costs

Merchants Bancorp's shares fell 9.3% following its Q1 2026 earnings report, despite a headline beat. The decline was triggered by a nearly 50% drop in brokered deposits year-over-year and a significant increase in funding costs, raising investor concerns about the sustainability of earnings growth. A law firm has launched an investigation into potential federal securities law violations regarding prior strong deposit growth statements versus the lack of commentary on the recent steep decline in brokered deposits.

Original reporting
Published May 7, 2026, 3:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 7, 2026, 3:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$MBINM
Bearish
medium confidence
Mentioned
$MBINM
Relevance
6/10
AlphAI data visualization · based on Pluang
Decision brief

The 30-second read

$MBINMBearishMed
01

Why it matters

The deposit decline and funding cost increase threaten earnings sustainability, potentially leading to further stock price declines and sector contagion.

02

Market read

The news is highly relevant for traders focusing on regional banks, especially those with similar deposit structures or exposure to brokered deposits.

03

What to watch

Possible support levels at recent lows; broader economic conditions and interest rate trends may influence recovery.

Relevance 6/10Timing: Immediate to short-term (next 1-4 weeks)

Background

Merchants Bancorp reported strong earnings earlier but now faces deposit outflows and rising costs, raising concerns about liquidity and profitability.

Company-level read

Ticker impact

$MBINMBearishMedium confidence
Context

The news directly pertains to Merchants Bancorp (MBINM), highlighting significant deposit declines and rising funding costs.

Expected impact

Potential further decline of 3-5% in the short term if negative trends persist; long-term impact uncertain pending investigation outcomes.

Evidence & confidence

The decline is based on recent earnings and deposit data; however, the investigation introduces uncertainty, and technical indicators are not available for precise prediction.

Market effects

Potential negative impact on regional banking sector, especially institutions reliant on brokered deposits.

Likely to affect banking stocks in the U.S. regional markets.

Limited; primarily regional and sector-specific impact.

Counterpoint

The decline may be overdone if the investigation clears or if deposit declines stabilize; the stock could rebound if the bank demonstrates resilience.

Key entities

  • Merchants Bancorp

    Regional bank with significant brokered deposits and recent earnings growth.

  • Law Firm Investigation

    Legal investigation into potential securities law violations related to deposit disclosures.

Related articles

$MRNAHigh

MRNA Stock’s Vaccine Rally Cracks As Worst Week In 3 Months Looms — Analyst Calls It A ‘Do-Not-Trade’ Over Wild Swings

Moderna (MRNA) shares fell sharply, marking their worst week in three months. Analysts from Bernstein, TD Cowen, and BMO Capital Markets expressed mixed views on the company's cancer vaccine data, with price targets implying significant downside. Moderna reported a revenue decline in 2025 and aims for cash breakeven by 2028. Earnings are due on Nov. 6. Retail sentiment on Stocktwits remains bullish for both Moderna and Merck (MRK).

$RIOMed

Rio Tinto to invest USD1.9 billion in Kangwinan bauxite project

Rio Tinto PLC and Ltd will invest USD1.9 billion in the Kangwinan bauxite project in Queensland, Australia. The project aims to add 20 million tonnes of annual bauxite production capacity by 2032, replacing output from the Andoom mine. Construction is set to ramp up in 2027, supporting 1,300 jobs. Shares in Rio Tinto fell 2.2% to AUD147.05 in Sydney on Friday morning, according to the company and Alliance News.

$VERAMedAI 8/10

Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results

Vera Therapeutics (VERA) reported strong Phase III results for TRUTAKNA (atacicept) in IgA nephropathy, with mild/moderate adverse events and no serious safety concerns. The drug received accelerated FDA approval in July and is being commercially launched. Vera plans to submit a supplemental biologics license application this quarter, aiming for full approval in mid-2027.

$INTCHigh

KOSPI Breaks Below 5,400 as Philadelphia Semiconductor Index Plunges 6.7%; SK Hynix's Solidigm IPO Halt Fails to Lift Sentiment

South Korea's KOSPI and KOSDAQ indices fell over 4% as U.S. semiconductor stocks plunged 6.7%, driven by foreign selling. SK Hynix halted Solidigm's IPO, citing market conditions. Samsung Electronics and SK Hynix shares dropped 4% and 3%, respectively. Meta's AI spending plans also weighed on sentiment, with oil prices rising on geopolitical tensions.